BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Cervical cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Treatment
50 results:

  • 1. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
    Wong RW; Cheung ANY
    Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
    Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Bhatla N; Joshi S; Pimple S; Kawade A; Balasubramani L; Thomas A; Suri V; Lalwani S; Uday R; Kamath V; Mandal R; Rajeswar A; Peedicayil A; Poli UR; Banerjee D; Sankaranarayanan R; Basu P; Muwonge R; Gairola S; Dogar V; Rao H; Shaligram U
    Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Improvement in neck ultrasound report quality following the implementation of European Thyroid Association guidelines for postoperative cervical ultrasound for thyroid cancer follow-up, a prospective population study.
    Wu J; Hu X; Seal P; Amin P; Diederichs B; Paschke R
    Eur Thyroid J; 2023 Aug; 12(5):. PubMed ID: 37439446
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Association of MicroRNA-10b Expression and P16 with Pathological Features in Various Stages of cervical Precancerous Lesions.
    Deng Y; Jiang H; Wu D
    Cell Mol Biol (Noisy-le-grand); 2023 Jan; 69(1):109-113. PubMed ID: 37213147
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with brca1 mutation.
    Nei T; Tamauchi S; Ikeda Y; Yoshikawa N; Niimi K; Kajiyama H
    J Obstet Gynaecol Res; 2023 Jul; 49(7):1875-1879. PubMed ID: 37114359
    [TBL] [Abstract] [Full Text] [Related]  

  • 6.
    Darabi S; Braxton DR; Xiu J; Carneiro BA; Swensen J; Antonarakis ES; Liu SV; McKay RR; Spetzler D; El-Deiry WS; Demeure MJ
    Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557020
    [No Abstract]    [Full Text] [Related]  

  • 7. BARD1 mystery: tumor suppressors are cancer susceptibility genes.
    Hawsawi YM; Shams A; Theyab A; Abdali WA; Hussien NA; Alatwi HE; Alzahrani OR; Oyouni AAA; Babalghith AO; Alreshidi M
    BMC Cancer; 2022 Jun; 22(1):599. PubMed ID: 35650591
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Bioinformatics Screening of Potential Biomarkers from mRNA Expression Profiles to Discover Drug Targets and Agents for cervical cancer.
    Reza MS; Harun-Or-Roshid M; Islam MA; Hossen MA; Hossain MT; Feng S; Xi W; Mollah MNH; Wei Y
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409328
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Study of 172 Cases of AIDS Associated cancers.
    Phatak UA; Gosavi VS; Chitale PV
    J Assoc Physicians India; 2022 Jan; 70(1):11-12. PubMed ID: 35062808
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Genomic Correlates of Unfavorable Outcome in Locally Advanced cervical cancer Treated with Neoadjuvant Chemoradiation.
    Wei Y; Wei C; Chen L; Liu N; Ou Q; Yin JC; Pang J; Fang Z; Wu X; Wang X; Mu D; Shao Y; Yu J; Yuan S
    Cancer Res Treat; 2022 Oct; 54(4):1209-1218. PubMed ID: 35038823
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The Improving Risk Informed HPV Screening (iris) Study: Design and Baseline Characteristics.
    Gage JC; Raine-Bennett T; Schiffman M; Clarke MA; Cheung LC; Poitras NE; Varnado NE; Katki HA; Castle PE; Befano B; Chandra M; Rydzak G; Lorey T; Wentzensen N
    Cancer Epidemiol Biomarkers Prev; 2022 Feb; 31(2):486-492. PubMed ID: 34789470
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. New Cu(II) coordination polymer inhibits cervical cancer development by regulating brca1 protein via miR-9-5p.
    Zhang L; Li WP
    J Inorg Biochem; 2022 Jan; 226():111655. PubMed ID: 34740040
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a brca1 mutation carrier: a case report.
    Montero-Macias R; Koual M; Crespel C; Le Frére-Belda MA; Hélène HB; Nguyen-Xuan HT; Garinet S; Perkins G; Balay V; Durdux C; Florin M; Péré H; Bats AS
    J Med Case Rep; 2021 Apr; 15(1):210. PubMed ID: 33888155
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer.
    Brennan A; Brennan D; Rees M; Hickey M
    Int J Gynecol Cancer; 2021 Mar; 31(3):352-359. PubMed ID: 33127864
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.
    Chelariu-Raicu A; Zibetti Dal Molin G; Coleman RL
    Int J Gynecol Cancer; 2020 Oct; 30(10):1608-1618. PubMed ID: 32928926
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Effect of brca1 on the Concurrent Chemoradiotherapy Resistance of cervical Squamous Cell Carcinoma Based on Transcriptome Sequencing Analysis.
    Wen X; Liu S; Cui M
    Biomed Res Int; 2020; 2020():3598417. PubMed ID: 32685473
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Uterus transplantation: joys and frustrations of becoming a 'complete' woman-a qualitative study regarding self-image in the 5-year period after transplantation.
    Järvholm S; Enskog A; Hammarling C; Dahm-Kähler P; Brännström M
    Hum Reprod; 2020 Aug; 35(8):1855-1863. PubMed ID: 32619006
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer.
    Gao S; Du S; Lu Z; Xin J; Gao S; Sun H
    Eur Radiol; 2020 Feb; 30(2):1191-1201. PubMed ID: 31493211
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy.
    Ittiamornlert P; Ruengkhachorn I
    BMC Cancer; 2019 Jan; 19(1):51. PubMed ID: 30630439
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.